宫颈癌占女性癌症死亡的大部分，主要发生在发展中国家。这种疾病的罪魁祸首是人乳头瘤病毒 (HPV)，它占宫颈癌病例的 90% 以上。病毒株产生的蛋白质有利于抑制细胞凋亡过程和宫颈细胞的持续生长，从而导致肿瘤生长。促血管生成生长因子，如成纤维细胞生长因子（FGF）、血管内皮生长因子（VEGF）、血管生成素和其他内皮生长因子（EGF）由肿瘤细胞和周围微环境分泌，进一步促进癌症的发展。受体酪氨酸激酶的胞外结构域被配体（如 VEGF 和 EGF）利用，通过诱导受体二聚化来接合和激活它们，从而促进这些因子的级联影响。每个受体的酪氨酸激酶结构域彼此自磷酸化，激活受体并启动信号级联，促进血管生成、迁移、增殖和内皮细胞的存活。癌细胞受益于其改变的信号通路，从而导致致癌激活。早期宫颈癌检测后，二线治疗策略包括使用 VEGF 和小分子酪氨酸激酶抑制剂 (TKI) 阻断信号通路。这篇综述论文通过深入研究现有抑制剂的细节，强调了宫颈癌的起源以及使用 VEGF 和酪氨酸激酶抑制剂来对抗宫颈癌。此外，我们还讨论了目前处于临床试验各个阶段的抑制剂分子。本文必将增进人们对宫颈癌及其治疗方法的理解，以及可以采取哪些进一步的干预措施来减轻目前作为发展中国家主要健康负担的疾病。© 2024。作者，获得独家许可Springer Science Business Media, LLC，隶属于 Springer Nature。

Cervical cancer accounts for most deaths due to cancer in women, majorly in developing nations. The culprit behind this disease is the human papillomavirus (HPV) which accounts for more than 90% of cervical cancer cases. The viral strains produce proteins that favor the knocking down of the apoptosis process and continuous growth of cells in the cervix leading to tumor growth. Proangiogenic growth factors, such as fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietins, and other endothelial growth factors (EGF), are secreted by tumor cells and the surrounding microenvironment, which further advances the development of cancer. The extracellular domain of receptor tyrosine kinases is employed by ligands (like VEGF and EGF) to engage and activate them by inducing receptor dimerization, which facilitates the cascade impact of these factors. The tyrosine kinase domains of each receptor autophosphorylate each other, activating the receptor and initiating signaling cascades that promote angiogenesis, migration, proliferation, and survival of endothelial cells. Cancer cells benefit from its modified signaling pathways, which cause oncogenic activation. Upon early cervical cancer detection, the second-line therapy strategy involves blocking the signaling pathways with VEGF and small molecule tyrosine kinase inhibitors (TKIs). This review paper highlights the genesis of cervical cancer and combating it using VEGF and tyrosine kinase inhibitors by delving into the details of the currently available inhibitors. Further, we have discussed the inhibitor molecules that are currently in various phases of clinical trials. This paper will surely enhance the understanding of cervical cancer and its treatment approaches and what further interventions can be done to alleviate the disease currently serving as a major health burden in the developing world.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.